DDInter1168 DDInter1376
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methdilazine {u} (Compound) resembles {v} (Compound) Thioproperazine
Methdilazine {u} (Compound) resembles {v} (Compound) Epinastine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methdilazine {u} (Compound) binds {v} (Gene) HRH1
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Deutetrabenazine
Methdilazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Methdilazine (Compound) resembles Thioproperazine (Compound)
Methdilazine (Compound) resembles Epinastine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methdilazine (Compound) binds HRH1 (Gene)
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Methdilazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Methdilazine may lead to a major life threatening interaction when taken with Deutetrabenazine
Methdilazine (Compound) resembles Perphenazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine